Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 8/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.36 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051475 | 0.87 | PIK3C3 (0.46) | PIK3C3JAK2JAK1TYK2ABL1 | |
| SCHEMBL15050900 | 0.81 | JAK2 (0.42) | PIK3C3JAK2JAK1TYK2ABL1 | |
| SCHEMBL15051712 | 0.81 | PIK3C3 (0.40) | PIK3C3JAK2MALT1JAK1TYK2 | |
| SCHEMBL15051493 | 0.77 | ABL1 (0.47) | ABL1 | |
| SCHEMBL950371 | 0.72 | MAPK1 (0.40) | JAK2MALT1 | |
| SCHEMBL15050993 | 0.71 | CDK9 (0.46) | PIK3C3ABL1 | |
| SCHEMBL15051578 | 0.69 | PIK3C3 (0.43) | PIK3C3JAK2JAK1TYK2ABL1 | |
| SCHEMBL15058203 | 0.66 | JAK2 (0.42) | PIK3C3JAK2JAK1TYK2ABL1 | |
| SCHEMBL9107473 | 0.66 | PIK3C3 (0.43) | PIK3C3JAK2JAK1TYK2ABL1 | |
| SCHEMBL626529 | 0.65 | IKBKB (0.47) | PIK3C3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | claimed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | PIK3C3 143/4885JAK2 610/4885MALT1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.